FDA approves first siRNA drug for myasthenia gravis, dosed just four times a year
Cemdisiran, a C5-silencing siRNA, improved daily function and muscle strength in a 24-week phase III trial of AChR-positive myasthenia gravis, with a boxed infection warning.
Summary
The FDA has approved cemdisiran (Livsayis), the first small interfering RNA (siRNA) therapy for generalized myasthenia gravis in adults with anti-acetylcholine receptor antibodies. The drug silences complement component 5 (C5), blocking the immune cascade that damages the connection between nerve and muscle. In the 24-week phase III NIMBLE trial, patients on cemdisiran improved 2.3 points more than placebo on a patient-reported daily-living scale and 2.8 points more on a physician-rated muscle strength score. Benefit appeared as early as 2 weeks. It is injected under the skin four times a year. Serious adverse events were less common than with placebo, but the drug carries a boxed warning for life-threatening meningococcal infection and is available only through a restricted safety program. Patients must follow meningococcal vaccination recommendations. It is the second C5 inhibitor approved for the condition in one week.
Detailed Summary
Myasthenia gravis is an autoimmune disease in which antibodies attack the acetylcholine receptors where nerves signal muscles. The result is fluctuating, sometimes profound weakness that can affect speaking, vision, breathing and movement. Preserving muscle function and independence is a core healthspan concern, and this approval adds a new tool for people living with the condition.
The FDA approved cemdisiran (Livsayis) for adults with generalized myasthenia gravis who are anti-AChR antibody-positive. It is a small interfering RNA that silences production of complement component 5 (C5), curbing terminal complement activation, a key driver of tissue damage in this form of the disease. It is the first siRNA approved for myasthenia gravis and the second C5 inhibitor cleared in a week, after gefurulimab.
Approval rested on the 24-week phase III NIMBLE trial. On the primary outcome, the patient-reported MG-ADL score improved 4.5 points with cemdisiran versus 2.2 with placebo, an adjusted difference of 2.3 points (P=0.0005), with gains seen by week 2. On the physician-administered QMG muscle function score, improvement was 4.2 versus 1.5 points, an adjusted difference of 2.8 (P=0.0015).
Adverse events occurred in 69% of the cemdisiran group and 77% of the placebo group. Serious events were 3% versus 14%. Upper respiratory infection was most common (12% versus 11%). No serious or meningococcal infections occurred on cemdisiran. Two deaths occurred after the double-blind period; one, from pneumonia, was judged treatment-related by the investigator but not by the sponsor.
Practically, dosing is subcutaneous, four times a year, which is far less frequent than other options. However, it carries a boxed warning for serious meningococcal infection, requires a REMS program and meningococcal vaccination. Caveats: the evidence covers 24 weeks, and long-term safety, durability and comparisons with other C5 inhibitors are not addressed. Details come from a news report relaying company data.
Key Findings
- Cemdisiran is the first siRNA approved for AChR-positive generalized myasthenia gravis; it silences C5 to block terminal complement activation.
- Phase III NIMBLE (24 weeks): MG-ADL improved 2.3 points more than placebo (P=0.0005), with gains as early as 2 weeks.
- Physician-rated QMG muscle function improved 2.8 points more than placebo (P=0.0015) at 24 weeks.
- Serious adverse events were 3% versus 14% on placebo; no meningococcal infections, but a boxed warning and REMS program apply.
- Two post-treatment-period deaths occurred; the investigator, but not the sponsor, deemed the pneumonia death treatment-related.
Methodology
This is a news report on an FDA approval, based on the sponsor's announcement and the 24-week randomized, placebo-controlled phase III NIMBLE trial. MedPage Today is a credible trade outlet, but figures come via company data rather than the full publication. Evidence covers function (MG-ADL, QMG) in humans; no survival or long-term outcomes are reported.
Study Limitations
The report is brief and lacks absolute trial size, population details, durability beyond 24 weeks and head-to-head comparison with other C5 inhibitors. The disputed causality of one death and the meningococcal risk warrant review of the full label and trial publication. Real-world safety and cost remain unknown.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
